
Toll Like Receptor 4 (hToll or CD284 or TLR4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Toll Like Receptor 4 (hToll or CD284 or TLR4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Toll Like Receptor 4 (hToll or CD284 or TLR4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL).
Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 40 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 4, 17 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively. Report covers products from therapy areas Infectious Disease, Gastrointestinal, Oncology, Central Nervous System, Respiratory, Immunology, Cardiovascular, Genito Urinary System And Sex Hormones, Dermatology, Undisclosed, Ear Nose Throat Disorders, Musculoskeletal Disorders and Other Diseases which include indications Coronavirus Disease 2019 (COVID-19), Non-Alcoholic Steatohepatitis (NASH), Autoimmune Hepatitis, Inflammation, Non Alcoholic Fatty Liver Disease (NAFLD), Allergic Rhinitis, Bacterial Sepsis, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Dengue Fever, Influenza A Virus, H1N1 Subtype Infections, Kidney Fibrosis, Liver Fibrosis, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Pain, Respiratory Syncytial Virus (RSV) Infections, Sepsis, Solid Tumor, Acute Ischemic Stroke, Acute Lung Injury, Acute On Chronic Liver Failure (ACLF), Allergic Asthma, Alzheimer's Disease, Atherosclerosis, Bronchopulmonary Dysplasia, Chronic Asthma, Chronic Liver Disease, Chronic Obstructive Pulmonary Disease (COPD), Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), Contact Dermatitis, Coronavirus Disease 2019 (COVID-19) Pneumonia, Crohn's Disease (Regional Enteritis), Cyst, Drug Addiction, Endotoxemia, Escherichia coli Infections, Follicular Lymphoma, Food Allergy, Hearing Disorders, Human Papillomavirus (HPV) Associated Cancer, Inflammatory Bowel Disease, Influenza A Virus, H5N1 Subtype Infections, Influenzavirus B Infections, Intracerebral Hemorrhage, Kidney Disease (Nephropathy), Low Back Pain, Lung Cancer, Marginal Zone B-cell Lymphoma, Merkel Cell Carcinoma, Migraine, Multiple Sclerosis, Myocardial Infarction, Nasal Congestion, Necrotizing Enterocolitis, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Post-Operative Pain, Prostate Cancer, Pseudomonas aeruginosa Infections, Pulmonary Edema, Pulmonary Inflammation, Rhinovirus Infections, Schistosomiasis, Soft Tissue Sarcoma, Unspecified, Unspecified B-Cell Lymphomas, Unspecified Cancer, Unspecified Dermatological Disorders, Unspecified Infectious Diseases, Unspecified Rare Disease and Viral Respiratory Tract Infection.
The latest report Toll Like Receptor 4 - Drugs In Development, 2022, outlays comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Toll Like Receptor 4 (hToll or CD284 or TLR4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL).
Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 40 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 4, 17 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively. Report covers products from therapy areas Infectious Disease, Gastrointestinal, Oncology, Central Nervous System, Respiratory, Immunology, Cardiovascular, Genito Urinary System And Sex Hormones, Dermatology, Undisclosed, Ear Nose Throat Disorders, Musculoskeletal Disorders and Other Diseases which include indications Coronavirus Disease 2019 (COVID-19), Non-Alcoholic Steatohepatitis (NASH), Autoimmune Hepatitis, Inflammation, Non Alcoholic Fatty Liver Disease (NAFLD), Allergic Rhinitis, Bacterial Sepsis, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Dengue Fever, Influenza A Virus, H1N1 Subtype Infections, Kidney Fibrosis, Liver Fibrosis, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Pain, Respiratory Syncytial Virus (RSV) Infections, Sepsis, Solid Tumor, Acute Ischemic Stroke, Acute Lung Injury, Acute On Chronic Liver Failure (ACLF), Allergic Asthma, Alzheimer's Disease, Atherosclerosis, Bronchopulmonary Dysplasia, Chronic Asthma, Chronic Liver Disease, Chronic Obstructive Pulmonary Disease (COPD), Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), Contact Dermatitis, Coronavirus Disease 2019 (COVID-19) Pneumonia, Crohn's Disease (Regional Enteritis), Cyst, Drug Addiction, Endotoxemia, Escherichia coli Infections, Follicular Lymphoma, Food Allergy, Hearing Disorders, Human Papillomavirus (HPV) Associated Cancer, Inflammatory Bowel Disease, Influenza A Virus, H5N1 Subtype Infections, Influenzavirus B Infections, Intracerebral Hemorrhage, Kidney Disease (Nephropathy), Low Back Pain, Lung Cancer, Marginal Zone B-cell Lymphoma, Merkel Cell Carcinoma, Migraine, Multiple Sclerosis, Myocardial Infarction, Nasal Congestion, Necrotizing Enterocolitis, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Post-Operative Pain, Prostate Cancer, Pseudomonas aeruginosa Infections, Pulmonary Edema, Pulmonary Inflammation, Rhinovirus Infections, Schistosomiasis, Soft Tissue Sarcoma, Unspecified, Unspecified B-Cell Lymphomas, Unspecified Cancer, Unspecified Dermatological Disorders, Unspecified Infectious Diseases, Unspecified Rare Disease and Viral Respiratory Tract Infection.
The latest report Toll Like Receptor 4 - Drugs In Development, 2022, outlays comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)
- The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
111 Pages
- Introduction
- Global Markets Direct Report Coverage
- Toll Like Receptor 4 (hToll or CD284 or TLR4) – Overview
- Toll Like Receptor 4 (hToll or CD284 or TLR4) – Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Toll Like Receptor 4 (hToll or CD284 or TLR4) – Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Toll Like Receptor 4 (hToll or CD284 or TLR4) – Companies Involved in Therapeutics Development
- 13therapeutics Inc
- Acepre LLC
- Akaza Bioscience Ltd
- Allodynic Therapeutics LLC
- Apollo Therapeutics LLC
- AptaTargets SL
- Ayuvis Research Inc
- Celestial Therapeutics Inc
- Douleur Therapeutics Inc
- Edesa Biotech Inc
- EyeGene Inc
- FasCure Therapeutics LLC
- Genesen Co Ltd
- Immunovo BV (Inactive)
- Inimmune Corp
- Kupando GmbH
- Lubris Biopharma
- Merck & Co Inc
- Pattern Pharma Inc
- Protara Therapeutics Inc
- Revelation Biosciences Inc
- Soin Therapeutics LLC
- TaiwanJ Pharmaceuticals Co Ltd
- Vascular Biogenics Ltd
- Xalud Therapeutics Inc
- Toll Like Receptor 4 (hToll or CD284 or TLR4) – Drug Profiles
- (clonidine + naltrexone) – Drug Profile
- ApTOLL – Drug Profile
- AVR-48 – Drug Profile
- Biologic to Agonize TLR4 for Drug Addiction – Drug Profile
- Biologics to Antagonize TLR4 for Dengue Fever – Drug Profile
- C-34 – Drug Profile
- CIA-05 – Drug Profile
- CT-02 – Drug Profile
- DT-001 – Drug Profile
- ECF-843 – Drug Profile
- G-100 – Drug Profile
- GS-200 – Drug Profile
- INI-2004 – Drug Profile
- ISAS-01 – Drug Profile
- KUP-101 – Drug Profile
- naltrexone – Drug Profile
- naltrexone hydrochloride – Drug Profile
- naltrexone hydrochloride CR – Drug Profile
- P-13 – Drug Profile
- P-7 – Drug Profile
- P-MAPA – Drug Profile
- P2PAR-100 – Drug Profile
- paridiprubart – Drug Profile
- PEPA-10 – Drug Profile
- resatorvid – Drug Profile
- REVTX-100 – Drug Profile
- REVTx-99 – Drug Profile
- Small Molecule to Antagonize TLR4 for Gastrointestinal Disorders – Drug Profile
- Small Molecule to Inhibit TLR2 and TLR4 for Bacterial Sepsis – Drug Profile
- Small Molecules to Antagonize TLR2 and TLR4 for Pulmonary Edema, Inflammation and Sepsis – Drug Profile
- Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis – Drug Profile
- Small Molecules to Antagonize TLR4 for Chronic Obstructive Pulmonary Disease, Chronic Asthma and Alzheimer’s Disease – Drug Profile
- Small Molecules to Antagonize TLR4 for Dengue Fever – Drug Profile
- Synthetic Peptide to Antagonize TLR4 for Sepsis – Drug Profile
- Synthetic Peptide to target TLR-4 for Oncology, Inflammation and Infectious Disease – Drug Profile
- TARA-002 – Drug Profile
- TJC-0133 – Drug Profile
- VB-201 – Drug Profile
- VB-703 – Drug Profile
- XT-203 – Drug Profile
- Toll Like Receptor 4 (hToll or CD284 or TLR4) – Dormant Products
- Toll Like Receptor 4 (hToll or CD284 or TLR4) – Discontinued Products
- Toll Like Receptor 4 (hToll or CD284 or TLR4) – Product Development Milestones
- Featured News & Press Releases
- Dec 20, 2022: FDA grants fast track to Edesa Biotech's ARDS drug candidate
- Dec 01, 2022: Protara Therapeutics announces trials in progress poster presentation for the ADVANCED-1 trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology
- Sep 30, 2022: Edesa Biotech reports statistically significant mortality reductions in phase 2 ARDS drug study
- Aug 01, 2022: AyuVis selected for MassChallenge Accelerator 2022 Cohort
- Jul 22, 2022: Revelation Biosciences announces topline data for phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis
- Jul 14, 2022: Revelation Biosciences inc. completes database lock for its phase 1b clear clinical study of REVTx-99b for the treatment of allergic rhinitis
- Jul 11, 2022: Edesa Biotech to present at ARDS Drug Development Summit
- Jun 13, 2022: Revelation Biosciences announces completion of dosing for a phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis
- May 26, 2022: Protara Therapeutics announces trials in progress poster presentation for the ADVANCED-1 trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting
- May 24, 2022: Edesa Biotech adds mechanically ventilated patients to phase 3 ARDS study
- May 23, 2022: Revelation Biosciences announces Safety Monitoring Committee recommendation for continuing evaluation of REVTx-99b for the treatment of allergic rhinitis
- May 13, 2022: AyuVis awarded $1.8M grant to support pediatric drug development program
- May 12, 2022: Protara Therapeutics presents results from retrospective analysis of randomized and open-label studies evaluating the safety and efficacy of OK-432 in patients with lymphatic malformations
- Mar 31, 2022: AyuVis receives second patent approval from USPTO, Australia
- Mar 30, 2022: aptaTargets initiates dosing with ApTOLL in Phase Ib Covid-19 trial
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development by Stage of Development, 2022
- Table 2: Number of Products under Development by Therapy Areas, 2022
- Table 3: Number of Products under Development by Indications, 2022
- Table 4: Number of Products under Development by Indications, 2022 (Contd..1)
- Table 5: Number of Products under Development by Indications, 2022 (Contd..2)
- Table 6: Number of Products under Development by Indications, 2022 (Contd..3)
- Table 7: Number of Products under Development by Companies, 2022
- Table 8: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 9: Products under Development by Companies, 2022
- Table 10: Products under Development by Companies, 2022 (Contd..1)
- Table 11: Products under Development by Companies, 2022 (Contd..2)
- Table 12: Products under Development by Companies, 2022 (Contd..3)
- Table 13: Products under Development by Companies, 2022 (Contd..4)
- Table 14: Number of Products under Investigation by Universities/Institutes, 2022
- Table 15: Products under Investigation by Universities/Institutes, 2022
- Table 16: Number of Products by Stage and Mechanism of Actions, 2022
- Table 17: Number of Products by Stage and Route of Administration, 2022
- Table 18: Number of Products by Stage and Molecule Type, 2022
- Table 19: Pipeline by 13therapeutics Inc, 2022
- Table 20: Pipeline by Acepre LLC, 2022
- Table 21: Pipeline by Akaza Bioscience Ltd, 2022
- Table 22: Pipeline by Allodynic Therapeutics LLC, 2022
- Table 23: Pipeline by Apollo Therapeutics LLC, 2022
- Table 24: Pipeline by AptaTargets SL, 2022
- Table 25: Pipeline by Ayuvis Research Inc, 2022
- Table 26: Pipeline by Celestial Therapeutics Inc, 2022
- Table 27: Pipeline by Douleur Therapeutics Inc, 2022
- Table 28: Pipeline by Edesa Biotech Inc, 2022
- Table 29: Pipeline by EyeGene Inc, 2022
- Table 30: Pipeline by FasCure Therapeutics LLC, 2022
- Table 31: Pipeline by Genesen Co Ltd, 2022
- Table 32: Pipeline by Immunovo BV (Inactive), 2022
- Table 33: Pipeline by Inimmune Corp, 2022
- Table 34: Pipeline by Kupando GmbH, 2022
- Table 35: Pipeline by Lubris Biopharma, 2022
- Table 36: Pipeline by Merck & Co Inc, 2022
- Table 37: Pipeline by Pattern Pharma Inc, 2022
- Table 38: Pipeline by Protara Therapeutics Inc, 2022
- Table 39: Pipeline by Revelation Biosciences Inc, 2022
- Table 40: Pipeline by Soin Therapeutics LLC, 2022
- Table 41: Pipeline by TaiwanJ Pharmaceuticals Co Ltd, 2022
- Table 42: Pipeline by Vascular Biogenics Ltd, 2022
- Table 43: Pipeline by Xalud Therapeutics Inc, 2022
- Table 44: Dormant Products, 2022
- Table 45: Dormant Products, 2022 (Contd..1)
- Table 46: Dormant Products, 2022 (Contd..2)
- Table 47: Dormant Products, 2022 (Contd..3)
- Table 48: Dormant Products, 2022 (Contd..4)
- Table 49: Dormant Products, 2022 (Contd..5)
- Table 50: Discontinued Products, 2022
- Table 51: Discontinued Products, 2022 (Contd..1)
- List of Figures
- Figure 1: Number of Products under Development by Stage of Development, 2022
- Figure 2: Number of Products under Development by Therapy Areas, 2022
- Figure 3: Number of Products under Development by Top 10 Indications, 2022
- Figure 4: Number of Products by Mechanism of Actions, 2022
- Figure 5: Number of Products by Stage and Mechanism of Actions, 2022
- Figure 6: Number of Products by Routes of Administration, 2022
- Figure 7: Number of Products by Stage and Routes of Administration, 2022
- Figure 8: Number of Products by Top 10 Molecule Types, 2022
- Figure 9: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.